RSV Vaccines: TGA Advice on how to avoid errors

The Therapeutic Goods Administration (TGA) has put out an alert after receiving 84 reports as of June this year, of administration errors relating to Abrysvo, Arexvy and nirsevimab, involving the products being administered outside of the current clinical recommendations.

Read the TGAs Advice on how to avoid errors

Key Points:

  • The National Immunisation Program (NIP) provides the free maternal RSV vaccine Abrysvo® to eligible women at 28 to 36 weeks of pregnancy.
  • States and territories offer the infant Beyfortus™ (nirsevimab) RSV monoclonal antibody product. This product is covered through state and territory RSV infant protection programs. Contact your local PHU for any questions regarding eligibility and access.
  • People aged 60 and over, Aboriginal and Torres Strait Islander people aged 60 and over, and people with medical risk conditions may consider purchasing RSV vaccines through the private market. However, these cannot be reimbursed through the NIP or state and territory programs.

Respiratory syncytial virus (RSV) products Program advice for health professionals

Share RSV Vaccines: TGA Advice on how to avoid errors on Facebook Share RSV Vaccines: TGA Advice on how to avoid errors on Twitter Share RSV Vaccines: TGA Advice on how to avoid errors on Linkedin Email RSV Vaccines: TGA Advice on how to avoid errors link